KDM1A and breast carcinoma: Our results defined an effective target drug for KDM1A as one that shows a significantly high negative correlation between KDM1A expression and LN IC50 in Pearson correlation analysis As a result, we identified the following 6 anticancer drugs as those that can most effectively reduce the growth of breast cancer cells with high KDM1A expression: alisertib, MK-2206, dinaciclib, vorinostat, camptothecin, and entinostat (Figure 6).